MVA-5T4

AXP000184.1 · Cancer vaccine

Platform
MVA
Targets
TPBG
Originator
Oxford BioMedica
Sponsor
Oxford BioMedica

Names

NameTypeSource
MVA-5T4preferred name, codecurator, ncit
TroVaxbrandncit
OXB-301codencit

Virus

Role
Vaccine vector
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Strain
MVA
Replication
non replicating
Modifications
human 5T4 (TPBG) cassette inserted into MVA
Transgenes
TPBG
Source
evidence

Cross-references

NCI Thesaurus
C49087
FDA UNII
P258UUW1OD

Approvals

No regulatory approval recorded.

Clinical trials (11)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT02390063Vaccination in Prostate Cancer (VANCE)CompletedPhase 12015-062018-05-1540Prostate Cancer
NCT01556841The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian CancerCompletedPhase 22013-112019-04-1994Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
NCT01569919A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural MesotheliomaUnknownPhase 22012-122014-0626Malignant; Mesothelioma; Pleural
NCT01194960TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)TerminatedPhase 22010-082013-0325Hormone Refractory Prostate Cancer
NCT00521274Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate CancerTerminatedPhase 22007-082008-0711Prostatic Neoplasms
NCT00397345TroVax Renal Immunotherapy Survival TrialCompletedPhase 32006-092009-12733Clear Cell Renal Carcinoma
NCT00448409Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate CancerCompletedPhase 22006-052007-0427Prostatic Neoplasms
NCT00445523Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal CancerCompletedPhase 22006-052008-0128Carcinoma, Renal Cell
NCT00325507Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell CarcinomaCompletedPhase 22005-112008-0725Carcinoma, Renal Cell
NCT00083941A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell CancerCompletedPhase 22004-082008-0725Carcinoma, Renal Cell
NCT00259844Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases RemovedCompletedPhase 22004-0620Colorectal Neoplasms

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 38760075A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC).International journal of gynecological cancer : official journal of the International Gynecological Cancer Society2024cited by trial NCT01556841
PMID 32591433Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.Journal for immunotherapy of cancer2020cited by trial NCT02390063
PMID 28880972Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.JAMA oncology2017name in abstract: MVA-5T4
PMID 23877659Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial.Cancer immunology, immunotherapy : CII2013cited by trial NCT01194960
PMID 22692758Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax).Cancer immunology, immunotherapy : CII2012name in title: TroVax
PMID 21387109MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.Cancer immunology, immunotherapy : CII2011name in title: MVA-5T4
PMID 20881001Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study.Clinical cancer research : an official journal of the American Association for Cancer Research2010cited by trial NCT00397345
PMID 20948436Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients.Journal of immunotherapy (Hagerstown, Md. : 1997)2010name in title: TroVax
PMID 19128501Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.Journal of translational medicine2009cited by trial NCT00083941
PMID 19342962Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha.Journal of immunotherapy (Hagerstown, Md. : 1997)2009name in title: TroVax
PMID 19561532Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial.Journal of immunotherapy (Hagerstown, Md. : 1997)2009name in title: TroVax
PMID 18060404Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.Cancer immunology, immunotherapy : CII2008name in title: TroVax
PMID 18528296Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial.Journal of immunotherapy (Hagerstown, Md. : 1997)2008name in title: TroVax
PMID 18833005An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases.Journal of immunotherapy (Hagerstown, Md. : 1997)2008name in abstract: TroVax
PMID 19010868Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial.Clinical cancer research : an official journal of the American Association for Cancer Research2008cited by trial NCT00325507
PMID 17671134Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.Clinical cancer research : an official journal of the American Association for Cancer Research2007name in title: TroVax
PMID 16740766Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.Clinical cancer research : an official journal of the American Association for Cancer Research2006name in title: TroVax

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 30524880A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial.Oncoimmunology2018name in title: TroVax
PMID 28504837Immunotherapy for metastatic renal cell carcinoma.The Cochrane database of systematic reviews2017name in abstract: MVA-5T4
PMID 25262701Clinical outcomes model in renal cell cancer patients treated with modified vaccinia Ankara plus tumor-associated antigen 5T4.The International journal of biological markers2015name in abstract: MVA-5T4
PMID 25483641TroVax in colorectal cancer.Human vaccines & immunotherapeutics2014name in title: TroVax
PMID 23603858Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.Journal of immunotherapy (Hagerstown, Md. : 1997)2013name in abstract: MVA-5T4
PMID 23875174Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4.Frontiers in oncology2013name in title: MVA-5T4
PMID 22149999TroVax(®) vaccine therapy for renal cell carcinoma.Immunotherapy2012name in title: TroVax
PMID 22253556Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer.Clinical Medicine Insights. Oncology2012name in title: TroVax
PMID 22409460Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.Future oncology (London, England)2012name in title: MVA-5T4
PMID 22892449CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model.Journal of immunotherapy (Hagerstown, Md. : 1997)2012name in abstract: MVA-5T4
PMID 21691576An update on TroVax for the treatment of progressive castration-resistant prostate cancer.OncoTargets and therapy2011name in title: TroVax
PMID 200887185T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.Expert opinion on biological therapy2010name in abstract: TroVax
PMID 20975327TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development.Human vaccines2010name in title: TroVax
PMID 19221742Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).Cancer immunology, immunotherapy : CII2009name in title: TroVax
PMID 18004564CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells.Cancer immunology, immunotherapy : CII2008name in abstract: TroVax
PMID 18567615Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4.International immunology2008name in abstract: TroVax
PMID 18990081Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer.Expert opinion on biological therapy2008name in abstract: MVA-5T4
PMID 177273345T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy.Expert opinion on biological therapy2007name in abstract: TroVax
PMID 17922073Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2007name in abstract: MVA-5T4
PMID 16311730Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated.Cancer immunology, immunotherapy : CII2006name in title: TroVax
PMID 16630022Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4.Immunology2006name in abstract: TroVax
PMID 16179960Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2005name in abstract: MVA-5T4
PMID 14988742Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2004name in abstract: MVA-5T4
PMID 15468602Technology evaluation: TroVax, Oxford BioMedica.Current opinion in molecular therapeutics2004name in title: TroVax
PMID 12481437Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors.Molecular cancer therapeutics2002name in abstract: MVA-5T4

Notes

TroVax: MVA encoding the oncofetal antigen 5T4 (TPBG); trials in colorectal, renal and prostate cancer, including the phase 3 TRIST study in renal cell carcinoma (NCT00397345) - the phase 3 designation and result were not verified from a primary source in this pass. Also carries the Oxford BioMedica code OXB-301.

How to cite

MVA-5T4 (AXP000184.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000184.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.